Echosens
Edit

Echosens

http://www.echosens.com/
Last activity: 24.10.2022
Tags:DiagnosticsEdTechHardwareHealthTechITManagementMedTechProductResearchTechnology
Echosens™, founded in 2001, is a French high-technology company specialising in non-invasive diagnostics for use in hepatology. Echosens™ is very active in research and development, and currently holds patents from 17 different fields, focusing mainly on its key technology: Vibration-Controlled Transient Elastography (VCTE™). n innovative technology: Vibration-Controlled Transient Elastography (VCTE) Echosens™ is the inventor of a highly innovative technology: pulse elastography. This has caused a fundamental change in the clinical practice of hepatologists. Echosens develops and markets the FibroScan®, a unique device for the diagnosis and monitoring of liver disease. The examination is non-invasive, fast, and painless. With more than 660 publications, FibroScan® with its dedicated probes is the elastography device with by far the most evidence to demonstrate its clinical usefulness. The best-performing range of blood tests on the market Applying the same philosophy, FibroMeter™ scores combine several biological markers to predict the presence of fibrosis in the liver. This complete range of blood scores, developed by Prof. Calès's team at the Angers teaching hospital in France, has given rise to the publication of many articles in world-class scientific journals, and is covered by a series of patents. Echosens™ devotes a significant proportion of its activity to research, with the aim of developing new medical devices and opening up new medical horizons. The company works in close collaboration with health professionals and patients' associations to facilitate the therapeutic monitoring of patients. To date, more than 2000 FibroScan® units have been installed all over the world. Structure
Likes
1420
Mentions
2
Location: France, Ile-de-France, Paris
Employees: 201-500
Phone: +33 1 44 82 78 50
Founded date: 2001

Investors 3

Mentions in press and media 2

DateTitleDescriptionSource
24.10.2022Echosens and ChronWell Announce Exclusive Strategic Partners...“NAFLD and NASH remain a silent and dangerous epidemic for over 80 million Americans. We are proud t...prweb.com/...
-Innovative, Non-Invasive Technologies Advanced Earlier Detec...Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways ...hitconsult...